Browsing Tag
Novo Nordisk
103 posts
How oral obesity drugs are changing treatment access: A look at semaglutide, amycretin, and orforglipron
Oral GLP-1 drugs like semaglutide, amycretin, and orforglipron are redefining obesity care. Explore trial data, payer impact, and what’s ahead for access and scale.
Can dual agonist drugs like amycretin and tirzepatide replace bariatric surgery by 2030?
Can new obesity drugs like amycretin and tirzepatide replace bariatric surgery by 2030? Discover what clinical data and cost trends reveal about the future.
How Novo Nordisk is building a post-semaglutide strategy: Inside its metabolic pipeline and innovation bets
Novo Nordisk pivots beyond semaglutide with amycretin, CagriSema, and oral GLP-1 therapies. See how it’s building its next-generation obesity drug platform.
How are GLP-1 drugs like Wegovy and Zepbound reshaping obesity care beyond weight loss in 2025?
GLP-1 drugs like Wegovy and Zepbound are reshaping obesity care in 2025, with benefits extending to cardiovascular, liver, and kidney health. Learn more now.
Novo Nordisk advances amycretin to phase 3 after early data show weight loss of up to 24% in obesity trials
Novo Nordisk moves amycretin to phase 3 after early trials show up to 24% weight loss. See what makes this dual-receptor drug a next-gen obesity contender.
Novo Nordisk’s high-dose Wegovy delivers 21% weight loss in STEP UP Phase 3 trial results
Novo Nordisk’s high-dose Wegovy led to 21% weight loss in a Phase 3 trial. Learn what the STEP UP data means for obesity care and future regulatory plans.
Deep Apple Therapeutics signs $812m global deal with Novo Nordisk for oral cardiometabolic drugs
Deep Apple inks up to $812M deal with Novo Nordisk to advance oral GPCR drugs for obesity and metabolic diseases. Explore the science behind the strategy.
Why Alzheimer’s partnerships with Roche, BMS, and Novo Nordisk still matter for Prothena
Explore how Prothena’s strategic collaborations with Roche, BMS, and Novo Nordisk could shape the future of Alzheimer’s drug development.
Prothena halts birtamimab development after Phase 3 AFFIRM-AL trial fails to meet endpoints
Prothena ends birtamimab development after failed Phase 3 trial in AL amyloidosis. Find out how this impacts its pipeline, financials, and future direction.
Hims & Hers Health soars over 10% after Wegovy rollout, Q1 strength, and analyst upgrades
Hims & Hers Health stock jumped 10.36% on May 16, 2025, after a Wegovy rollout, strong Q1 earnings, and analyst upgrades boosted investor confidence.